The effectiveness of pharmaceutical PD-L1 inhibition depends on the amount of PD-L1 on the surface of tumor cells, with PD-L1-positive tumors showing a better response to (chemo)immunotherapy compared to PD-L1-negative tumors. Here, CD274 is linked to neoplasm.